MarketCap
Facebook
X
Telegram
Puma Biotechnology ROCE Ratio | PBYI
Annual ROCE Ratio Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.62 | 33.61 | 61.08 | 109.77 | -52.74 | 510.87 | -26.32 | -49.31 | -272.79 | -128.45 | -115.85 | -120.25 | -64.43 | -57.27 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 510.87 | -272.79 | -10.25 |
Quarterly ROCE Ratio Puma Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.14 | 15.76 | 49.8 | 37.01 | 26.16 | 22.06 | 44.22 | 29.25 | 50.63 | 55.14 | 65.94 | 104.87 | 78.32 | 61.44 | 143.42 | 76.17 | 137.65 | 148.1 | 351.95 | 150.18 | 446.09 | 323.53 | 240.79 | -110.68 | 65.5 | -173.97 | -206.85 | -244.92 | -165.49 | -221.88 | -367.17 | -480.96 | -497.49 | -429.3 | -460.75 | -347.15 | -234.43 | -97.09 | -126.57 | -126.63 | -120.48 | -86.52 | -117.25 | -121.0 | -106.43 | -80.89 | -97.96 | -82.36 | -63.18 | -46.25 | -66.32 | -60.72 | -54.78 | -40.73 | -41.34 | -21.33 | -9.88 | -0.68 | -0.61 | -0.06 | -0.01 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 446.09 | -497.49 | -45.39 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Oncolytics Biotech
ONCY
|
-584.69 | $ 0.45 | 5.32 % | $ 43.1 M |  Canada |
 |
ORIC Pharmaceuticals
ORIC
|
-37.21 | $ 8.47 | -9.37 % | $ 744 M |  USA |
 |
Oramed Pharmaceuticals
ORMP
|
-7.12 | $ 3.91 | -5.45 % | $ 162 M |  Israel |
 |
PDS Biotechnology Corporation
PDSB
|
-340.95 | $ 1.17 | -10.0 % | $ 54.3 M | USA |
 |
Pfizer
PFE
|
10.69 | $ 30.03 | -2.47 % | $ 171 B | USA |
 |
Pharming Group N.V.
PHAR
|
23.99 | $ 12.53 | 0.56 % | $ 8.63 B |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
-125.87 | $ 5.07 | -10.83 % | $ 370 M | USA |
 |
Pliant Therapeutics
PLRX
|
-86.3 | $ 0.81 | -4.85 % | $ 49.7 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-9.85 | $ 2.51 | -6.69 % | $ 197 M | Israel |
 |
PMV Pharmaceuticals
PMVP
|
-82.33 | $ 1.28 | -3.4 % | $ 67.3 M | USA |
 |
PTC Therapeutics
PTCT
|
44.91 | $ 65.61 | -4.87 % | $ 5.22 B | USA |
 |
BioVie
BIVI
|
-95.03 | $ 1.21 | -9.7 % | $ 1.79 M | USA |
 |
Protagonist Therapeutics
PTGX
|
-25.72 | $ 135.02 | -6.05 % | $ 8.58 B | USA |
 |
Pulmatrix
PULM
|
-35.98 | $ 1.46 | -4.28 % | $ 5.33 B | USA |
 |
Sage Therapeutics
SAGE
|
-92.97 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.01 | - | - | $ 1.62 B | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
-83.6 | $ 2.44 | -6.7 % | $ 271 M | USA |
 |
Arcus Biosciences
RCUS
|
-61.17 | $ 17.96 | -6.92 % | $ 1.93 B | USA |
 |
Cabaletta Bio
CABA
|
-149.87 | $ 1.26 | -10.92 % | $ 127 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-34.91 | - | - | $ 958 M | USA |
 |
Relay Therapeutics
RLAY
|
-50.82 | $ 17.0 | -5.74 % | $ 2.92 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-60.1 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
7.56 | - | - | $ 26.6 B |  Irlanda |
 |
Avidity Biosciences
RNA
|
-44.18 | $ 8.34 | -3.92 % | $ 1.15 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
27.02 | - | - | $ 121 M | USA |
 |
Royalty Pharma plc
RPRX
|
8.21 | $ 67.55 | -0.02 % | $ 29 B | USA |
 |
Revolution Medicines
RVMD
|
-57.28 | $ 177.88 | -10.93 % | $ 33.8 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-379.93 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Rhythm Pharmaceuticals
RYTM
|
-78.92 | $ 105.13 | -5.01 % | $ 6.83 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
349.59 | $ 0.42 | 0.62 % | $ 5.18 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-480.0 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-27.03 | - | - | $ 411 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-24.29 | $ 3.69 | -2.25 % | $ 234 M | USA |
 |
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.39 | -8.42 % | $ 279 M | USA |
 |
Seelos Therapeutics
SEEL
|
120.86 | - | -47.76 % | $ 6.27 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-31.74 | $ 63.01 | -4.53 % | $ 176 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-39.9 | $ 7.84 | -14.28 % | $ 855 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-66.67 | $ 9.34 | -10.67 % | $ 809 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Spero Therapeutics
SPRO
|
10.7 | $ 1.02 | -4.82 % | $ 57.1 M | USA |
 |
Kiromic BioPharma
KRBP
|
188.88 | - | 6.61 % | $ 3.08 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-353.49 | $ 4.01 | -7.6 % | $ 1.78 M | USA |
 |
Geron Corporation
GERN
|
-14.94 | $ 0.95 | -11.87 % | $ 633 M | USA |
 |
Stoke Therapeutics
STOK
|
-5.71 | $ 26.09 | -4.95 % | $ 1.55 B | USA |
 |
Calithera Biosciences
CALA
|
-206.33 | - | -10.95 % | $ 876 K | USA |
 |
Sutro Biopharma
STRO
|
119.57 | $ 9.16 | -7.8 % | $ 77.8 M | USA |